A5080826945- Colorectal Cancer Treatments and Studies
- Lung Cancer Treatments and Mutations
- Estrogen and related hormone effects
- Cancer Treatment and Pharmacology
- Breast Cancer Treatment Studies
- Gastric Cancer Management and Outcomes
- Lung Cancer Research Studies
- Cancer Genomics and Diagnostics
- Hepatocellular Carcinoma Treatment and Prognosis
- Colorectal Cancer Surgical Treatments
- Nutrition, Genetics, and Disease
- Cancer Risks and Factors
- Genetic factors in colorectal cancer
- Neuroblastoma Research and Treatments
- Cancer therapeutics and mechanisms
- HER2/EGFR in Cancer Research
- Colorectal and Anal Carcinomas
- Neuroendocrine Tumor Research Advances
- Advanced Breast Cancer Therapies
- Neonatal Respiratory Health Research
- Reproductive Biology and Fertility
- Cancer Immunotherapy and Biomarkers
- Pancreatic and Hepatic Oncology Research
- Neutropenia and Cancer Infections
- Lung Cancer Diagnosis and Treatment
Ospedale Policlinico San Martino
2020-2025
Italian Oncology Group of Clinical Research
2019-2025
Tumour Institute of Tuscany
2012-2024
University of Florence
2012-2022
Alleanza Contro il Cancro
1994-2022
Azienda Ospedaliero-Universitaria Careggi
2012-2021
Ospedale Papa Giovanni XXIII
2020
Ospedale Santa Chiara
2000-2019
Azienda Ospedaliero-Universitaria di Modena
2019
Ninewells Hospital
2018
A fluoropyrimidine plus irinotecan or oxaliplatin, combined with bevacizumab (a monoclonal antibody against vascular endothelial growth factor), is standard first-line treatment for metastatic colorectal cancer. Before the introduction of bevacizumab, chemotherapy fluorouracil, leucovorin, and (FOLFOXIRI) showed superior efficacy as compared (FOLFIRI). In a phase 2 study, FOLFOXIRI promising activity an acceptable rate adverse effects.We randomly assigned 508 patients untreated cancer to...
To investigate oxaliplatin combined with fluorouracil-based chemoradiotherapy as preoperative treatment for locally advanced rectal cancer.Seven hundred forty-seven patients resectable, (cT3-4 and/or cN1-2) adenocarcinoma of the mid-low rectum were randomly assigned to receive pelvic radiation (50.4 Gy in 28 daily fractions) and concomitant infused fluorouracil (225 mg/m(2)/d) either alone (arm A, n = 379) or (60 mg/m(2) weekly × 6; arm B, 368). Overall survival is primary end point. A...
Premenopausal patients with breast cancer are at high risk of premature ovarian failure induced by systemic treatments, but no standard strategies for preventing this adverse effect yet available.To determine the temporary suppression obtained administering gonadotropin-releasing hormone analogue triptorelin during chemotherapy on incidence early menopause in young undergoing adjuvant or neoadjuvant chemotherapy.The PROMISE-GIM6 (Prevention Menopause Induced Chemotherapy: A Study Early...
Whether the administration of luteinizing hormone-releasing hormone analogues (LHRHa) during chemotherapy is a reliable strategy to preserve ovarian function controversial owing both lack data on long-term and pregnancies safety concerns about potential negative interactions between endocrine therapy chemotherapy.To evaluate results LHRHa-induced suppression breast cancer chemotherapy.Parallel, randomized, open-label, phase 3 superiority trial conducted at 16 Italian sites. Between October...
Tamoxifen administered for 5 years at 20 mg/d is effective in breast cancer treatment and prevention, but toxicity has limited its broad use. Biomarker trials showed that not inferior to decreasing proliferation. We hypothesized a lower dose given shorter period could be as preventing recurrence from intraepithelial neoplasia have than the standard dose.We conducted multicenter randomized trial of tamoxifen, or placebo 3 after surgery women with hormone-sensitive unknown neoplasia, including...
Five-year data of the phase III trial TAM-01 showed that low-dose tamoxifen at 5 mg once daily administered for 3 years in women with intraepithelial neoplasia (IEN) reduced by 52% recurrence invasive breast cancer or ductal carcinoma situ (DCIS), without additional adverse events over placebo. Here, we present 10-year results.We randomly assigned 500 IEN (atypical hyperplasia, lobular [LCIS], hormone-sensitive unknown DCIS) to placebo after surgery irradiation. The primary end point was...
Purpose Considering promising results in phase II studies, a randomized III trial was designed to assess the efficacy of adding bevacizumab first-line cisplatin plus etoposide for treatment extensive-disease (ED) small-cell lung cancer (SCLC). Patients and Methods Treatment-naive patients with ED-SCLC were randomly assigned receive either (arm A) or same regimen B) maximum six courses. In absence progression, arm B continued alone until disease progression 18 The primary end point overall...
Purpose On the assumption that most infants with disseminated neuroblastoma without MYCN amplification (MYCNA) have a favorable prognosis, two concomitant prospective trials were started in which chemotherapy was limited to patients presenting life- or organ-threatening symptoms overt metastases skeleton, lung, CNS. Surgery be performed only absence of surgical risk factors. Patients and Methods One hundred seventy MYCNA, diagnosed between June 1999 2004 nine European countries eligible for...
Studies suggest that giving newly born preterm infants sustained lung inflation (SLI) may decrease their need for mechanical ventilation (MV) and improve respiratory outcomes.We randomly assigned at 25 weeks 0 days to 28 6 of gestation receive SLI (25 cm H2O 15 seconds) followed by nasal continuous positive airway pressure (nCPAP) or nCPAP alone in the delivery room. were delivered using a neonatal mask T-piece ventilator. The primary end point was MV first 72 hours life. secondary points...
Neutrophil/lymphocyte ratio (NLR), defined as absolute neutrophils count divided by lymphocytes count, has been reported poor prognostic factor in several neoplastic diseases but only a few data are available about unresectable metastatic colorectal cancer (mCRC) patients (pts). The aim of our study was to evaluate the and predictive role NLR TRIBE trial.Pts enrolled trial were included. is multicentre phase III randomizing previously untreated mCRC pts receive FOLFOXIRI or FOLFIRI plus...
The combination of a triple-drug chemotherapy regimen with an anti-epidermal growth factor receptor (EGFR) agent as first-line treatment metastatic colorectal cancer (mCRC) showed promising activity along safety concerns in single-arm phase 2 trials. role maintenance following and anti-EGFR the optimal to be adopted are not established.To evaluate cetuximab plus modified FOLFOXIRI (mFOLFOXIRI) explore or bevacizumab RAS BRAF wild-type mCRC.In prospective, noncomparative, open-label,...
Abstract Subjects increasing sperm DNA fragmentation (sDF) during Density Gradient Centrifugation (DGC), a common selection procedure in Assisted Reproduction Techniques (ARTs), experience 50% lower probability of pregnancy. Hence, identification these subjects is clinical importance. Here, we investigated whether such are identified with higher accuracy detecting viable (viable sDF) instead total spermatozoa (total and swim up, an alternative to DGC, does not increase sDF. With 10/20 sDF, 2...
Background: Right-sided metastatic colorectal cancer (mCRC) patients have poor prognosis and achieve limited benefit from first-line doublets plus a targeted agent.In this unplanned analysis of the TRIBE study, we investigated prognostic predictive impact primary tumor sidedness in mCRC differential intensification chemotherapy subgroups defined according to both RAS BRAF mutational status.Patients methods: Patients were randomized receive upfront 5-fluoruracil, leucovorin, irinotecan...